DavidEMoodyMD

PubMed

• Could postnatal age-related uridine diphosphate glucuronic acid be a rate-limiting factor in the metabolism of morphine during the first week of life?
  Liu, T.,Lewis, T. R.,Moore, J. N.,Kraft, W. K.,Gauda, E. B.,Sartori, D.,Moody, D. E.,Gobburu, JVS.,Ivaturi, V.> ;CPT Pharmacometrics Syst Pharmacol. 2019 May 03
• HASH(0x3211ae8)
  Moody, D. E.> ;Expert Opin Drug Saf. 2018 Aug 18
• Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial.
  Briones, M., Shoptaw, S., Cook, R., Worley, M. J., Swanson, A., Moody, D. E., Fang, W. B., Tsuang, J., Furst, B. A., Heinzerling, K. G.> ;Drug and alcohol dependence. 2018 Jun 4
• Inhibition of In Vitro Metabolism of Opioids by Skeletal Muscle Relaxants.
  Moody, D. E.,Fu, Y.,Fang, W. B.> ;Basic Clin. Pharmacol. Toxicol.. 2018 Mar 06
• The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.
  Moore, J. N.,Gastonguay, M. R.,Ng, C. M.,Adeniyi-Jones, S. C.,Moody, D. E.,Fang, W. B.,Ehrlich, M. E.,Kraft, W. K.> ;Clin. Pharmacol. Ther.. 2018 Mar 09
• Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil.
  Grasing, K., Mathur, D., DeSouza, C., Newton, T. F., Moody, D. E., Sturgill, M. G.> ;The American journal on addictions. 2016 Jul 9
• 8 citations
  Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome.
  Ng, C. M., Dombrowsky, E., Lin, H., Erlich, M. E., Moody, D. E., Barrett, J. S., Kraft, W. K.> ;Pharmacotherapy. 2015 Jul 15
• A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Correc...
  Carlquist, J. F., Moody, D. E., Knight, S., Johnson, E. G., Fang, W. B., Huntinghouse, J. A., Rollo, J. S., Webster, L. R., Anderson, J. L.> ;Molecular diagnosis & therapy. 2015 Apr 24
• 3 citations
  The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection.
  Tetrault, J. M., McCance-Katz, E. F., Moody, D. E., Fiellin, D. A., Lruie, B. S., DInh, A. T., Fiellin, L. E.> ;Journal of substance abuse treatment. 2014 Dec 7
• 1 citation
  Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.
  Masson, C. L., Rainey, P. M., Moody, D. E., McCance-Katz, E. F.> ;The American journal on addictions. 2013 Dec 10
• 14 citations
  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
  Bruce, R. D., Moody, D. E., Altice, F. L., Gourevitch, M. N., Friedland, G. H.> ;Expert review of clinical pharmacology. 2013 May 10
• 10 citations
  Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.
  Moody, D. E.> ;Expert opinion on drug metabolism & toxicology. 2013 Mar 30
• Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
  Bruce, R. D., Moody, D. E., Chodkowski, D., Andrews, L., Fang, W. B., Morrison, J., Parsons, T. L., Friedland, G. H.> ;The American journal of drug and alcohol abuse. 2013 Feb 21
• 1 citation
  Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.
  Michelle R. Lofwall, David E. Moody, Wenfang B. Fang, Paul A. Nuzzo, Sharon L. Walsh> ;The Journal of Clinical Pharmacology. 2012 Apr 1
• Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.
  McCance-Katz, E. F., Moody, D. E., Prathikanti, S., Friedland, G., Rainey, P. M.> ;Drug and alcohol dependence. 2011 May 21
• Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
  Bruce, R. D., Moody, D. E., Fang, W. B., Chodkowski, D., Andrews, L., Friedland, G. H.> ;The American journal of drug and alcohol abuse. 2011 Mar 29
• 5 citations
  The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.
  Middleton, L. S., Nuzzo, P. A., Lofwall, M. R., Moody, D. E., Walsh, S. L.> ;Addiction (Abingdon, England). 2011 Mar 15
• 18 citations
  Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.
  Baker, J., Rainey, P. M., Moody, D. E., Morse, G. D., Ma, Q., McCance-Katz, E. F.> ;The American journal on addictions. 2010 Feb 6
• 11 citations
  Lack of clinically significant drug interactions between nevirapine and buprenorphine.
  McCance-Katz, E. F., Moody, D. E., Morse, G. D., Ma, Q., Rainey, P. M.> ;The American journal on addictions. 2010 Feb 6
• The Cardiovascular and Subjective Effects of Methamphetamine Combined with γ-vinyl-γ-aminobutyric acid (GVG) in Non-Treatment Seeking Methamphetamine-dependent Volunteers
  Richard De La Garza, Todd Zorick, Keith G. Heinzerling, Steve Nusinowitz, Edythe D. London, Steven Shoptaw, David E. Moody, Thomas F. Newton> ;Pharmacology, Biochemistry and Behavior. 2009 Nov 1
• 9 citations
  Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
  Bruce, R. D., Altice, F. L., Moody, D. E., Lin, S., Fang, W. B., Sabo, J. P., Wruck, J. M., Piliero, P. J., Conner, C., Andrews, L., Friedland, G. H.> ;Drug and alcohol dependence. 2009 Sep 4
• An enantiomer-selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine, and liver microsomes.
  Moody, D. E.,Lin, S. N.,Chang, Y.,Lamm, L.,Greenwald, M. K.,Ahmed, M. S.> ;J Anal Toxicol. 2008 Apr 10
• 39 citations
  Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.
  McCance-Katz, E. F., Moody, D. E., Morse, G. D., Ma, Q., DiFrancesco, R., Friedland, G., Pade, P., Rainey, P. M.> ;Drug and alcohol dependence. 2007 Jul 24
• Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
  DiFrancesco, R., Fischl, M. A., Donnelly, J., Zingman, B. S., McCance-Katz, E. F., Moody, D. E., Reichman, R. C., Gripshover, B., Morse, G. D.> ;Journal of pharmaceutical and biomedical analysis. 2007 Mar 30
• 11 citations
  Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.
  McCance-Katz, E. F., Moody, D. E., Morse, G. D., Friedland, G., Pade, P., Baker, J., Alvanzo, A., Smith, P. F., Ogundele, A. B., Jatlow, P., Rainey, P. M.> ;Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006 Nov 17
• Join now to see all